Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1972 1
1974 2
1975 1
1976 1
1982 1
1988 1
1989 2
1991 2
2000 1
2001 1
2002 1
2003 2
2005 1
2006 2
2007 3
2008 3
2009 1
2010 1
2011 2
2012 3
2013 3
2014 4
2015 10
2016 3
2017 4
2018 9
2019 12
2020 14
2021 10
2022 15
2023 14
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE-V Study Group. Rosmarin D, et al. N Engl J Med. 2022 Oct 20;387(16):1445-1455. doi: 10.1056/NEJMoa2118828. N Engl J Med. 2022. PMID: 36260792
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Lima RG, Witte MM, Xu W, ElMaraghy H, Natalie CR, Pierce E, Blauvelt A; ADhere Investigators. Simpson EL, et al. JAMA Dermatol. 2023 Feb 1;159(2):182-191. doi: 10.1001/jamadermatol.2022.5534. JAMA Dermatol. 2023. PMID: 36630140 Free PMC article. Clinical Trial.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Therapeutic applications of selenium nanoparticles.
Khurana A, Tekula S, Saifi MA, Venkatesh P, Godugu C. Khurana A, et al. Among authors: saifi ma. Biomed Pharmacother. 2019 Mar;111:802-812. doi: 10.1016/j.biopha.2018.12.146. Epub 2019 Jan 4. Biomed Pharmacother. 2019. PMID: 30616079 Free article. Review.
[A rare cause of small-bowel perforation].
Saifi M, Kienle P. Saifi M, et al. Chirurgie (Heidelb). 2022 Sep;93(9):899-901. doi: 10.1007/s00104-022-01640-9. Epub 2022 Apr 11. Chirurgie (Heidelb). 2022. PMID: 35403908 German. No abstract available.
Natural inhibitors: A sustainable way to combat aflatoxins.
Ahmad MM, Qamar F, Saifi M, Abdin MZ. Ahmad MM, et al. Among authors: saifi m. Front Microbiol. 2022 Dec 8;13:993834. doi: 10.3389/fmicb.2022.993834. eCollection 2022. Front Microbiol. 2022. PMID: 36569081 Free PMC article. Review.
119 results